GoodRx Holdings, Inc. — Director's Dealing 2021

Dec 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GoodRx Holdings, Inc. (GDRX)
CIK: 0001809519
Period of Report: 2021-12-09

Reporting Person: Azad Babak (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-09	Class A Common Stock	M	12500	$5.94	Acquired	17500	Direct
2021-12-09	Class A Common Stock	S	3770	$40.9582	Disposed	13730	Direct
2021-12-09	Class A Common Stock	S	8430	$42.1862	Disposed	5300	Direct
2021-12-09	Class A Common Stock	S	300	$42.68	Disposed	5000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-09	Stock Option (Right to Buy)	$5.94	M	12500	Disposed	2030-01-30	Class A Common Stock (12500)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of December 9, 2020, as amended September 2, 2021.

F2: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.65 to $42.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.66 to $42.72. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019.